[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352438-105":59,"doc-detail-352438-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","genetically-engineered-erbb2-overexpression-sensitizes-organoid-derived-tumors-to-checkpoint-inhibition-original-research","Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition - Original research","","ERBB2/HER2 is overexpressed or mutated in about 15% of gastric cancers, but its influence on the tumor microenvironment remains poorly defined. Using genetically engineered syngeneic organoid-based gastric cancer models, the study examines TME features with spectral flow cytometry, single-cell RNA sequencing, and TCR repertoire sequencing. Findings show ErbB2 drives CD4+ and CD8+ T-cell recruitment, chronic activation, and CD8+ clonal expansion, and supports combined ErbB2-targeted therapy with PD-1 checkpoint blockade.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genetically-engineered-erbb2-overexpression-sensitizes-organoid-derived-tumors-to-checkpoint-inhibition-original-research/352438/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genetically-engineered-erbb2-overexpression-sensitizes-organoid-derived-tumors-to-checkpoint-inhibition-original-research/352438.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does this study address about ERBB2 in gastric cancer?","Question",{"text":113,"@type":114},"It investigates how genetically driven ERBB2/ErbB2 overexpression affects the tumor microenvironment, especially T-cell infiltration and activation, rather than only tumor cell-intrinsic effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the tumor models and immune analyses performed?",{"text":118,"@type":114},"The study used genetically engineered ectopic and orthotopic syngeneic organoid-based gastric cancer models. Tumor and immune features were measured with spectral flow cytometry, single-cell RNA sequencing, and TCR repertoire sequencing, with interventions including anti-ErbB2 and anti-PD1 antibodies.",{"name":120,"@type":111,"acceptedAnswer":121},"What mechanistic and therapeutic effects did ErbB2 overexpression show?",{"text":122,"@type":114},"ErbB2 overexpression promoted micronuclei formation and interferon-responsive gene activation, leading to increased T-cell infiltration and clonal expansion. Combination therapy with PD-1 checkpoint blockade plus an ErbB2-targeting antibody reduced growth of ErbB2-expressing tumors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352438,1791034244,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Open access Original research  \nTo cite: He J, Kirsche L, Nascakova Z, et al.  \nGenetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition  \nin a syngeneic model of gastric cancer. Journal for ImmunoTherapy of Cancer 2026;14:e012976 . doi:10 . 1136/ jitc-2025-012976  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012976](jitc-2025-012976)) .  \nJH and LK contributed equally. Accepted 29 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland 2Department of Medical Oncology and Hematology, University of Zürich and  \nUniversity Hospital Zürich, Zurich, Switzerland 3Functional Genomics Center Zürich, University of Zürich and Federal Institute of Technology Zürich, Zürich, Switzerland  \nCorrespondence to  \nProfessor Anne Müller; [mueller@imcr.uzh.ch](mueller@imcr.uzh.ch)  \nGenetically engineered ErbB2 overexpression sensitizes organoidderived tumors to checkpoint inhibition in a syngeneic model of gastric cancer  \nJiazhuo He,1 Lydia Kirsche,1 Zuzana Nascakova,1 Francesco Manfredi,2  \nChiara F Magnani  ,2 Giovanni Papa,1 Flora Azizi,1 Peter Leary,1,3 Anne Müller  1  \nABSTRACT  \nBackground ERBB2/HER2 is overexpressed or mutated in ~15% of gastric cancers due to amplification or mutation of the ERBB2 locus. While the tumor cellintrinsic consequences of ERBB2 overexpression are well understood, much less is known about its effects on the tumor microenvironment.  \nMethods We have developed genetically engineered ectopic and orthotopic syngeneic models of organoidbased gastric cancer that have allowed us to study the tumor microenvironment of ErbB2-overexpressing tumors, using spectral flow cytometry, single cell RNA sequencing, and TCR repertoire sequencing. Interventions such as anti-Erbb2 and anti-PD1 antibody treatments were used as well.  \nResults We find that ErbB2 drives the infiltration of CD4+ and CD8+ T-cells, which express granzymes, FasL, and surface markers indicating chronic activation, and in the case of CD8+ T-cells, have undergone clonal expansion. The adoptive transfer of T-cells sorted from ErbB2-overexpressing tumors reduces the growth of ErbB2-expressing, but not control tumors in T-cell-deficient recipients. PD-1-specific checkpoint blockade synergizes with an ErbB2-targeting antibody to reduce the growth of ErbB2-expressing, but not control tumors. Mechanistically, ErbB2 overexpression results in micronuclei formation and the transcriptional activation of numerous interferonresponsive genes in vitro and in vivo; mice lacking the type I interferon receptor show higher engraftment rates and lower T-cell infiltration than wild-type controls. Conclusions The combined data indicate that  \nErbB2, perhaps by driving micronuclei formation, has immunogenic properties that manifest in the form of increased T-cell infiltration and expansion, which can be exploited therapeutically by combining PD1-directed checkpoint blockade with ErbB2-targeted therapy.  \nINTRODUCTION  \nHER2/ERBB2 is a receptor tyrosine kinaseencoded by the ERBB2 gene in humans (located on chromosome 17q12) and the Erbb2 gene on chromosome 11 in mice.1 HER2 does not have direct ligand-binding activity, but functions as the preferred heterodimerization partner for the three  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ ERBB2 amplification and/or mutation occurs most commonly in breast and gastric cancer and is often associated with dense lymphocytic infiltration. Patients with ERBB2/HER2-positive gastric or gastroesophageal junction adenocarcinoma benefit from the addition of the PD-1-targeting antibody pembrolizumab to trastuzumab and chemotherapy as first-line treatment.\u003Cbr>WHAT T","cbCainIjNgXJZRX3","https://ap.wps.com/l/cbCainIjNgXJZRX3","pdf",17197405,17,"English","# Abstract\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What question does this study address about ERBB2 in gastric cancer?\",\"answer\":\"It investigates how genetically driven ERBB2/ErbB2 overexpression affects the tumor microenvironment, especially T-cell infiltration and activation, rather than only tumor cell-intrinsic effects.\"},{\"question\":\"How were the tumor models and immune analyses performed?\",\"answer\":\"The study used genetically engineered ectopic and orthotopic syngeneic organoid-based gastric cancer models. Tumor and immune features were measured with spectral flow cytometry, single-cell RNA sequencing, and TCR repertoire sequencing, with interventions including anti-ErbB2 and anti-PD1 antibodies.\"},{\"question\":\"What mechanistic and therapeutic effects did ErbB2 overexpression show?\",\"answer\":\"ErbB2 overexpression promoted micronuclei formation and interferon-responsive gene activation, leading to increased T-cell infiltration and clonal expansion. Combination therapy with PD-1 checkpoint blockade plus an ErbB2-targeting antibody reduced growth of ErbB2-expressing tumors.\"}]","Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition - Original research | PDF",1790099634,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efd4434a482cb16d52c230ac8b4a836f.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ea4a2242c50824b768f11d447aa09fc.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69676b5d01936fcdab467da4c53b76c3.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6af8e394bfd38a24536f6143a20c84e9.webp",980,1306]